Literature DB >> 33436648

Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.

Mohamed K Hassan1,2, Amr A Waly3, Waheba Elsayed3, Sarah Keshk3,4, Walaa Ramadan Allam3, Sherif F El-Khamisy5,6,7.   

Abstract

Taxane is a family of front-line chemotherapeutic agents against ovarian cancer (OC). The therapeutic efficacy is frequently counteracted by the development of chemoresistance, leading to high rates of relapse in OC patients. The role(s) of microRNAs (miRNAs) in cancer chemoresistance had been supported by many evidences Epigenetic regulation by miRNAs has been reported to influence cancer development and response to therapeutics, however, their role in OC resistance to paclitaxel (PTX) is unclear. Here, we conducted miRNA profiling in the responsive and PTX-resistant OC cell lines before and after treatment with epigenetic modulators. We reveal 157 miRNAs to be downregulated in the PTX-resistant cells compared to parental controls. The expression of five miRNAs (miRNA-7-5p, -204-3p, -501-5p, -3652 and -4286) was restored after epigenetic modulation, which was further confirmed by qPCR. In silico analysis of the signaling pathways targeted by the selected miRNAs identified the PI3K-AKT pathway as the primary target. Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells. STRING analysis showed the deregulated genes in PTX-resistant cells to be primarily involved in cell cycle progression and survival. Thus, high throughput miRNA and cDNA profiling coupled with pathway analysis and data mining provide evidence for epigenetically regulated miRNAs-induced modulation of signaling pathways in PTX resistant OC cells. It paves the way to more in-depth mechanistic studies and new therapeutic strategies to combat chemoresistance.

Entities:  

Year:  2021        PMID: 33436648      PMCID: PMC7804410          DOI: 10.1038/s41598-020-78596-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

Review 1.  Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

Authors:  Szabolcs Modok; Howard R Mellor; Richard Callaghan
Journal:  Curr Opin Pharmacol       Date:  2006-05-11       Impact factor: 5.547

2.  Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Authors:  Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.

Authors:  Todd Boren; Yin Xiong; Ardeshir Hakam; Robert Wenham; Sachin Apte; Gina Chan; Siddharth G Kamath; Dung-Tsa Chen; Holly Dressman; Johnathan M Lancaster
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

4.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

5.  Akt regulates cell survival and apoptosis at a postmitochondrial level.

Authors:  H Zhou; X M Li; J Meinkoth; R N Pittman
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

6.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support.

Authors:  Ioannis S Vlachos; Konstantinos Zagganas; Maria D Paraskevopoulou; Georgios Georgakilas; Dimitra Karagkouni; Thanasis Vergoulis; Theodore Dalamagas; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2015-05-14       Impact factor: 16.971

7.  Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF.

Authors:  Dineo Khabele; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Valerie Montgomery Rice; Deok-Soo Son
Journal:  J Cancer       Date:  2014-09-05       Impact factor: 4.207

8.  KEGG: new perspectives on genomes, pathways, diseases and drugs.

Authors:  Minoru Kanehisa; Miho Furumichi; Mao Tanabe; Yoko Sato; Kanae Morishima
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

Review 9.  Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.

Authors:  Haller J Smith; J Michael Straughn; Donald J Buchsbaum; Rebecca C Arend
Journal:  Gynecol Oncol Rep       Date:  2017-03-21

Review 10.  Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy.

Authors:  Anna Maria Barbuti; Zhe-Sheng Chen
Journal:  Cancers (Basel)       Date:  2015-12-03       Impact factor: 6.639

View more
  1 in total

1.  Down-regulation of microRNA-155 suppressed Candida albicans induced acute lung injury by activating SOCS1 and inhibiting inflammation response.

Authors:  Xiaohua Li; Yuanzhong Gong; Xin Lin; Qiong Lin; Jianxiong Luo; Tianxing Yu; Junping Xu; Lifang Chen; Liyu Xu; Ying Hu
Journal:  J Microbiol       Date:  2022-02-14       Impact factor: 2.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.